Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

11.80 

2.33 24.6%

as of Nov 14 '19

52 Week Range:

6.24 19.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '16 Dec '17 Dec '18
Earnings BIT -8.83
-21.86
-47.91
growth rate 0.0% 0.0%
ROA -29.03
-43.58
growth rate 0.0%
ROE -677.61
growth rate
ROIC -705.21
growth rate
Cur. Ratio 6.99
8.22
growth rate 17.6%
Quick Ratio 6.83
7.40
growth rate 8.4%
Leverage 3.47
growth rate
Balance Sheet Dec '16 Dec '17 Dec '18
Acct.Receivable 0.39
0.02
1.03
growth rate -94.3% 4,568.2%
Acct.Payable 1.29
1.81
2.22
growth rate 40.4% 22.8%
Cur.Assets 94.40
64.33
115.68
growth rate -31.9% 79.8%
Total Assets 98.41
72.68
138.60
growth rate -26.2% 90.7%
Cash 93.42
62.80
103.19
growth rate -32.8% 64.3%
Cur.Liabilities 8.34
9.20
14.08
growth rate 10.4% 52.9%
Liabilities 103.16
99.05
98.64
growth rate -4.0% -0.4%
Equity -4.75
-26.37
39.96
growth rate 0.0% 100.0%
Common Shares 34.00
34.00
growth rate 0.0%
Cash Flow Statement Dec '16 Dec '17 Dec '18
Capital Expenditures 1.82
5.57
14.28
growth rate 206.6% 156.6%
Cash From OA 92.27
-24.17
-51.72
growth rate -100.0% 0.0%
FCF 90.46
-30.00
-67.00
growth rate -100.0% 0.0%
Income Statement Dec '16 Dec '17 Dec '18
Sales 7.02
6.48
10.88
growth rate -7.6% 67.8%
Op.Income -8.83
-21.86
-47.91
growth rate 0.0% 0.0%
IBT -8.26
-21.10
-46.04
growth rate 0.0% 0.0%
Net Income -8.25
-21.10
-46.04
growth rate 0.0% 0.0%
EPS -0.63
-1.37
growth rate 0.0%
Gross Profit 7.02
6.48
10.88
growth rate -7.6% 67.8%
R&D 9.23
19.49
43.69
growth rate 111.3% 124.2%

Quarterly Statements

Item Name Mar '18 Jun '18 Dec '18 Mar '19 Jun '19
Earnings BIT -9.24
-12.13
-16.11
-19.49
-23.87
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Mar '18 Jun '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 1.03
6.16
0.25
growth rate 499.5% -95.9%
Acct.Payable 2.22
5.06
2.88
growth rate 128.0% -43.0%
Cur.Assets 115.68
136.98
237.09
growth rate 18.4% 73.1%
Total Assets 138.60
166.80
271.92
growth rate 20.4% 63.0%
Cash 103.19
116.50
226.10
growth rate 12.9% 94.1%
Cur.Liabilities 14.08
71.38
15.82
growth rate 407.2% -77.8%
Liabilities 98.64
155.97
97.94
growth rate 58.1% -37.2%
Equity -26.37
39.96
10.83
173.98
growth rate 100.0% -72.9% 1,507.2%
Cash Flow Statement Mar '18 Jun '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 0.62
1.13
9.87
5.08
8.14
growth rate 82.2% 775.1% -48.5% 60.1%
Cash From OA -14.45
-9.31
-12.91
-19.91
-16.58
growth rate 0.0% 0.0% 0.0% 0.0%
FCF -15.07
-10.44
-22.78
-24.99
-24.71
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Mar '18 Jun '18 Dec '18 Mar '19 Jun '19
Sales 1.53
1.87
4.94
5.46
5.39
growth rate 22.6% 163.6% 10.6% -1.3%
Op.Income -9.24
-12.13
-16.11
-19.49
-23.87
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -9.01
-11.83
-15.44
-31.78
-19.44
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -9.01
-11.83
-15.44
-31.78
-19.44
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 1.53
1.87
4.94
5.46
5.39
growth rate 22.6% 163.6% 10.6% -1.3%
R&D 7.86
10.87
15.91
19.96
22.76
growth rate 38.3% 46.3% 25.5% 14.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -3.78 -3.69
EPS / Growth -3.12

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 50.0% 100.0%
Future PE 0.01 0.01 66.67
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.